Skip to content

Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01965340
Enrollment
39
Registered
2013-10-18
Start date
2013-10-31
Completion date
2016-10-31
Last updated
2016-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn

Keywords

patients

Brief summary

Sepsis is the major cause of morbidity and mortality amongst burn patients. Burn shock and respiratory failure that used to be the major cause of mortality have progressively been replaced by sepsis and multiple organ failure. It is not rare that treatment failures occurs several weeks, or even months after injury as a consequence of sepsis usually caused by multi-drug resistant (MDR) microorganisms. Introduction of early surgery combined with topical and systemic antibiotherapy dramatically enhanced survival from sepsis after burn trauma, but further improvement is impaired by the rapid development of hard-to-treat MDR bacteria. Correct prescription of anti-infective agents could be one way to curb the steadily increasing development of multidrug resistance. Administration of antibiotic to burn patient is complex: they frequently suffer from kidney dysfunction, they usually experience tremendous shifts of liquids between intra-vascular - inter-cellular and intra-cellular compartments, they often are hypo-albumin and protein-emic, and finally they present with a profoundly modified metabolism. All those aspects make this particular population of patients at high risk of both under or over prescription. Monitoring of drug concentrations in the plasma of patients, so-called TDM for Therapeutic Drug Monitoring, has been introduced to clinical practice for several decades primarily to avoid toxicity of a small number of drugs with narrow therapeutic windows. However, with the increasing availability of detection techniques, the number of drugs that can be measured in the plasma of patients has grown tremendously over the last decade. As a consequence, it is currently possible to monitor drug concentrations not only to prevent toxicity, but also to improve efficacy. For instance, several studies demonstrated that TDM improved antibiotic prescription in different populations of hospitalized patients, including critically ill patients, with a direct impact on outcome. Such studies amongst burn patients are however lacking, although this particular population is at high risk to suffer from mis-prescription. We thus hypothesize that systematic TDM could improve antibiotic prescription in this peculiar population. To this end, we propose to implement a 3-year prospective, randomized, mono-centric, clinical trial that will analyze the impact of systematic TDM on anti-infective agent prescription amongst burned patients.

Interventions

OTHERSystematic Therapeutic Drug Monitoring for the intervention group

Sponsors

University of Lausanne Hospitals
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult burn patients (≥ 18 years) admitted to the University Hospital of Lausanne during the study period receiving systemic anti-infectives agents for which TDM is available will be included.

Exclusion criteria

* Patients not receiving systemic anti-infective agents therapy * Patients with length of hospital stay \<72 hours * Patients refusing to give their written consent (or for which the therapeutic representative refuses) or incapable of understanding and lack of legal representative * Pregnant or breastfeeding women * Children \<18 years

Design outcomes

Primary

MeasureTime frame
Time required to achieve anti-infective plasma concentrations in the targetUp to 3 years
Numbers of concentrations within the target during an anti-infective agents courseUp to 3 years

Secondary

MeasureTime frameDescription
Length of ICU stay based on TBSAUp to 3 years
Characterization of the pharmacokinetic profile of most widely used antibioticsUp to 3 years
Anti-infective agents consumptionUp to 3 years
Failure / resolution rate of infectious episodesUp to 3 years
Concentration - toxicity analysisUp to 3 yearsPopulation pharmacokinetic (NONMEM software)
Concentration - efficacy analysisUp to 3 yearsPopulation pharmacokinetic (NONMEM software)
Development of antibiotic resistanceUp to 3 years

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026